Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Glucagon intranasal (Eli Lilly/Locemia Solutions) | AMG504-1; LY-900018 | Approved | Amg Medical, Locemia Solutions | Hypoglycemia | Details | |||||
Glucagon (rDNA origin, Novo Nordisk) | GL-G | Approved | Novo Nordisk A/S | GlucaGen, Glucagon G | Japan | Hypoglycemia | Novo Nordisk A/S | 1998-06-22 | Diabetes Mellitus, Type 1; Hypoglycemia; Obesity | Details |
Glucagon (Xeris Pharmaceuticals) | Approved | Xeris Pharmaceuticals Inc | Gvoke | United States | Hypoglycemia | Xeris Pharmaceuticals Inc | 1960-01-01 | Hypoglycemia; Hyperinsulinism | Details | |
Glucagon (rDNA origin, Lilly) | Approved | Eli Lilly And Company | Glucagon | United States | Hypoglycemia | Eli Lilly And Company | 1998-09-11 | Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity | Details | |
Glucagon | MP-123456B | Approved | Eli Lilly And Company | Baqsimi, Ogluo | EU | Hypoglycemia | Eli Lilly Nederland BV | 1960-11-14 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
Dasiglucagon | ZP-GA-1; ZP-4207 | Approved | Zealand Pharma A/S | Zegalogue | United States | Hypoglycemia | Zealand Pharma Us Inc | 2021-03-22 | Congenital Hyperinsulinism; Diabetes Mellitus, Type 1; Hypoglycemia; Hyperinsulinism; Glucose Metabolism Disorders | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PRT-001 | PRT-001 | Phase 3 Clinical | Particle Therapeutics | Hypoglycemia | Details |
PRT-003 | PRT-003 | Phase 1 Clinical | Particle Therapeutics | Details | |
Isosteviol | ISV; STX-03 | Phase 2 Clinical | Stevia Pharma | Diabetes Mellitus, Type 2 | Details |
Human glucagon(Shanghai Duomirui) | Phase 1 Clinical | Shanghai Duomirui Biotechnology Co Ltd | Hypoglycemia | Details | |
ISIS-325568 | ISIS-325568 | Ionis Pharmaceuticals Inc | Details | ||
MK-3577 | MK-3577 | Merck Sharp & Dohme Corp | Details | ||
IONIS-GCGRRx | IONIS-GCGRRx; ISIS-449884; ISISGCGRRx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Diabetes Mellitus, Type 2 | Details |
Bamadutide | SAR-425899 | Sanofi | Details | ||
MK-0893 | MK-0893; L-001241689 | Merck & Co Inc | Details | ||
PF-06291874 | PF-6291874; PF-06291874 | Pfizer Inc | Details | ||
MK-5823 | MK-5823 | Merck Sharp & Dohme Corp | Details | ||
MK-8521 | MK-8521 | Merck Sharp & Dohme Corp | Details | ||
LGD-6972 | LGD-6972; MB-11262; RVT-1502 | Ligand Pharmaceuticals Inc | Details | ||
Glucagon biosimilar (Hospira) | Hospira | Details | |||
BioChaperone Glucagon | BC Glucagon | Adocia | Details | ||
Efocipegtrutide | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) | Phase 2 Clinical | Pharmsynthez, Xenetic Biosciences Inc | Diabetes Mellitus, Type 2; Obesity | Details | |
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) | Phase 1 Clinical | Translational Research Institute For Metabolism And Diabetes | Obesity | Details | |
BI-456906 | BI-456906 | Phase 2 Clinical | Zealand Pharma A/S | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Liver Cirrhosis; Liver Diseases; Obesity; Overweight | Details |
DR-10624 | DR-10624 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Diabetes Mellitus | Details |
Pemvidutide | ALT-801(Altimmune); SP-1373; VPD-107 | Phase 2 Clinical | Velocity Pharmaceutical Development | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
RBD-4988 | RBD-4988 | Phase 2 Clinical | Suzhou Ruibo Biological Technology Co Ltd | Diabetes Mellitus, Type 2 | Details |
Efinopegdutide | JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Kidney Failure, Chronic | Details |
HM-15136 | HM-15136 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 | Details |
volagidemab | AMG-477; REMD-477 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus | Details |
TB-001 | TB001; TB-001 | Phase 1 Clinical | Shenzhen Tuwei Anchuang Technology Development Co Ltd | Non-alcoholic Fatty Liver Disease; Liver Cirrhosis | Details |
Cotadutide | MEDI-0382 | Phase 3 Clinical | Medimmune Llc | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Obesity; Renal Insufficiency, Chronic; Diabetes Mellitus | Details |
Mazdutide | OXM-3; IBI-362; LY-3305677 | Phase 3 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
retatrutide | LY-3437943 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Renal Insufficiency; Obesity; Overweight | Details |
DD-01 | DD-01 | Phase 1 Clinical | Neuraly Inc, D&D Pharmatech | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
PB-718 | PB-718 | Phase 1 Clinical | Peg Bio Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
This web search service is supported by Google Inc.